VSE knjižnice (vzajemna bibliografsko-kataložna baza podatkov COBIB.SI)
  • A three-dose mRNA COVID-19 vaccine regime produces both suitable immunogenicity and satisfactory efficacy in patients with solid cancers [Elektronski vir]
    Janžič, Urška, onkologinja ...
    Background: The recommended booster third dose of vaccination against COVID-19 in cancer patients seems reasonable to protect them against a severe disease course. A prospective study was designed to ... assess the immunogenicity, efficacy, and safety of COVID-19 vaccination in this cohort. Methods: Patients with solid malignancies on active treatment were followed up after the primary course and booster third dose of vaccination to assess their anti-SARS-CoV-2 S1 IgG levels, efficacy in the case of SARS-CoV-2 infection, and safety. Results: Out of 125 patients receiving the primary course of vaccination, 66 patients received a booster third dose of mRNA vaccine, with a 20-fold increase in median anti-SARS-CoV-2 S1 IgG levels compared to Ab levels six months post-primary course of vaccination (p < 0.0001). After the booster third dose, anti-SARS-CoV-2 S1 IgG levels were comparable to healthy controls (p = 0.113). There was a decline in Ab levels 3 (p = 0.0003) and 6 months (p < 0.0001) post-third booster dose. No patients had either a severe disease course or a lethal outcome in the case of SARS-CoV-2 infection after the third booster dose. Conclusion: The third booster vaccination dose against COVID-19 in solid cancer patients triggers substantial immunogenicity and is safe and effective for preventing a severe COVID-19 disease course.
    Vir: Vaccines [Elektronski vir]. - ISSN 2076-393X (Vol. 11, iss. 6, 2023, Str. 1-12)
    Vrsta gradiva - e-članek ; neleposlovje za odrasle
    Leto - 2023
    Jezik - angleški
    COBISS.SI-ID - 153238275

    Povezava(-e):

    https://www.mdpi.com/2076-393X/11/6/1017
    DOI

Vnos na polico